Key result
The MACH-1 trial was designed to evaluate whether mibefradil reduces mortality and improves symptoms in 2,400 patients with heart failure, with no results reported in this design abstract.
Why the study?
Does mibefradil reduce mortality in patients with symptomatic heart failure on standard therapy?
Population
2,400 patients with symptomatic heart failure in NYHA classes II-IV already treated with standard therapy
Comparison
Mibefradil added to standard therapy vs Placebo added to standard therapy
Design
Other, double-blind
Authors
Loading...
Launches RCT testing mibefradil addition in symptomatic HF; will determine if T-channel blockade reduces mortality on standard therapy.
RCT (n=2,400)
Double-blind
Yes
Does mibefradil reduce mortality in patients with symptomatic heart failure on standard therapy?
This paper describes the design of the MACH-1 trial, which aims to evaluate whether mibefradil reduces mortality in patients with symptomatic heart failure.
T. Barry Levine (1997) conducted an RCT in Congestive heart failure (n=2,400). Mibefradil vs. Placebo was evaluated on Mortality (survival) and symptoms of heart failure. The MACH-1 trial was designed to evaluate whether mibefradil reduces mortality and improves symptoms in 2,400 patients with heart failure, with no results reported in this design abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: